JP2017502983A - 不均一な腫瘍を処置するための患者特異的免疫療法 - Google Patents

不均一な腫瘍を処置するための患者特異的免疫療法 Download PDF

Info

Publication number
JP2017502983A
JP2017502983A JP2016546192A JP2016546192A JP2017502983A JP 2017502983 A JP2017502983 A JP 2017502983A JP 2016546192 A JP2016546192 A JP 2016546192A JP 2016546192 A JP2016546192 A JP 2016546192A JP 2017502983 A JP2017502983 A JP 2017502983A
Authority
JP
Japan
Prior art keywords
antibody
treatment
patient
tumor
clones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502983A5 (https=
Inventor
アビラム サリエル
アビラム サリエル
イラン ホフマン
イラン ホフマン
Original Assignee
スリ テクノロジーズ エルティーディー．
スリ テクノロジーズ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スリ テクノロジーズ エルティーディー．, スリ テクノロジーズ エルティーディー． filed Critical スリ テクノロジーズ エルティーディー．
Publication of JP2017502983A publication Critical patent/JP2017502983A/ja
Publication of JP2017502983A5 publication Critical patent/JP2017502983A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016546192A 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法 Pending JP2017502983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885511P 2013-10-02 2013-10-02
US61/885,511 2013-10-02
PCT/IL2014/050870 WO2015049688A2 (en) 2013-10-02 2014-10-02 Patient-specific immunotherapy for treating heterogeneous tumors

Publications (2)

Publication Number Publication Date
JP2017502983A true JP2017502983A (ja) 2017-01-26
JP2017502983A5 JP2017502983A5 (https=) 2018-08-16

Family

ID=52779242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546192A Pending JP2017502983A (ja) 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Country Status (5)

Country Link
US (2) US20160237163A1 (https=)
EP (2) EP3052933B1 (https=)
JP (2) JP2017502983A (https=)
CN (2) CN106133521A (https=)
WO (2) WO2015049688A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11728034B2 (en) 2019-09-02 2023-08-15 Canon Medical Systems Corporation Medical examination assistance apparatus

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113391A2 (en) * 2012-02-02 2013-08-08 Brainlab Ag Method for determining an infusion parameter
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
WO2016187711A1 (en) * 2015-05-22 2016-12-01 Csts Health Care Inc. Biomarker-driven molecularly targeted combination therapies based on knowledge representation pathway analysis
EP3298524A4 (en) 2015-05-22 2019-03-20 CSTS Health Care Inc. THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY
AU2016339022B2 (en) * 2015-10-12 2020-09-10 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CA3026236C (en) * 2016-06-03 2021-01-26 Samsung Life Public Welfare Foundation Method for screening antibody using patient-derived tumor spheroids
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
WO2019156254A1 (ja) * 2018-02-09 2019-08-15 アクシオンリサーチ株式会社 検査対象の複雑系の状態を推定するシステム
CN113597305B (zh) * 2019-03-15 2025-03-04 舒万诺知识产权公司 使用因果模型制造生物药物
US20220268762A1 (en) * 2019-07-28 2022-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
IL292346B2 (en) 2019-11-05 2025-02-01 Apeel Tech Inc Predicting contamination in plant products
JP2024527371A (ja) * 2021-07-08 2024-07-24 オウロテック インコーポレイテッド 処置の有効性予測システム及び方法
CN115153829B (zh) * 2022-06-23 2026-03-31 中国人民解放军空军军医大学 基于活性组织电阻抗信息非均匀重构的电脉冲消融模型精度优化方法
TWI909458B (zh) * 2024-05-17 2025-12-21 國防醫學大學 一種自體免疫疾病用藥預估方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06315395A (ja) * 1984-01-31 1994-11-15 Akzo Nobel Nv ヒトモノクローナル抗体の製法およびハイブリドーマの製法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
WO2002054171A2 (en) * 2000-12-06 2002-07-11 Biosentients, Inc. System, method, software architecture and business model for an intelligent object based information technology platform
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
US8926979B2 (en) * 2005-11-01 2015-01-06 Novartis Ag Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101646470B (zh) * 2007-03-27 2012-08-22 皇家飞利浦电子股份有限公司 基于由加速度传感器测量的患者活动状态的给药
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5734961B2 (ja) * 2009-05-29 2015-06-17 アスペン テクノロジー インコーポレイテッド 多変数プロセス制御においてモデルの品質を推定しモデルを適応させる装置およびその方法
EP2549399A1 (en) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
EP2844675B1 (en) * 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
CN104470843B (zh) 2012-07-18 2016-07-20 三菱电机株式会社 电梯装置
US9725768B2 (en) * 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
WO2014126198A1 (ja) * 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
ES2662598T3 (es) * 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06315395A (ja) * 1984-01-31 1994-11-15 Akzo Nobel Nv ヒトモノクローナル抗体の製法およびハイブリドーマの製法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 148, JPN6018027601, 2012, pages 886 - 895, ISSN: 0004002636 *
実験医学, vol. Vol.31(1), JPN6018027600, 2013, pages 8 - 13, ISSN: 0004002635 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11728034B2 (en) 2019-09-02 2023-08-15 Canon Medical Systems Corporation Medical examination assistance apparatus

Also Published As

Publication number Publication date
WO2015049688A3 (en) 2015-06-11
CN107207605A (zh) 2017-09-26
EP3201844A1 (en) 2017-08-09
WO2016051398A1 (en) 2016-04-07
JP2018500275A (ja) 2018-01-11
EP3052933A2 (en) 2016-08-10
WO2016051398A8 (en) 2016-06-02
US20160237163A1 (en) 2016-08-18
EP3052933A4 (en) 2017-05-17
US20180009901A1 (en) 2018-01-11
CN106133521A (zh) 2016-11-16
EP3201844A4 (en) 2018-05-02
WO2015049688A2 (en) 2015-04-09
EP3052933B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
JP2017502983A (ja) 不均一な腫瘍を処置するための患者特異的免疫療法
Kim et al. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma
Merlini AL amyloidosis: from molecular mechanisms to targeted therapies
JP6050466B2 (ja) 腫瘍特異的抗体及びその使用法
US11643456B2 (en) Human antibodies, pharmaceutical compositions and methods
JP6564408B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
CN109369808A (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
Shih Discovery process for antibody-based therapeutics
EA020465B1 (ru) ИЗОЛИРОВАННЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ErbB3, НАБОРЫ И КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И ИХ ПРИМЕНЕНИЕ
JP2018509385A (ja) がんの処置および検出のための組成物および方法
Yakushiji et al. Novel single‐chain variant of antibody against mesothelin established by phage library
Nielsen et al. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography
Luddy et al. Evolutionary double-bind treatment using radiotherapy and NK cell-based immunotherapy in prostate cancer
Tanaka et al. Antitumor activities by a humanized cancer‐specific anti‐podoplanin monoclonal antibody humPMab‐117 against human tumors
US20220389117A1 (en) Use of succinate as biomarker in diagnosis and treatment of cancers
US20140086840A1 (en) Therapeutic Antibody Target Validation and Screening In Vivo
Shi et al. Radionuclide-labeled antisilencing function 1a inhibitory peptides for tumor identification and individualized therapy
Jung et al. 89Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NF κ B and JNK Signaling
Di Meo et al. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Li et al. Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells
Rosenberg et al. DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease
US20210163591A1 (en) Compositions targeting gabra2 and methods for diagnosis and treatment of cancer
Serganova et al. A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses
Ghosh et al. Targeted Mass Spectrometry-Based Approach for the Determination of Intrinsic Internalization Kinetics of Cell-Surface Membrane Protein Targets
Pan et al. SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190326